Items where authors include "O’Malley, J.T."

Article

Weidinger, S., Bieber, T., Cork, M.J. orcid.org/0000-0003-4428-2428 et al. (8 more authors) (2023) Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. British Journal of Dermatology, 189 (5). pp. 531-539. ISSN 0007-0963

Blauvelt, A., Guttman-Yassky, E., Paller, A.S. et al. (13 more authors) (2022) Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis : results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE). American Journal of Clinical Dermatology, 23 (3). pp. 365-383. ISSN 1175-0561

Paller, A.S., Wollenberg, A., Siegfried, E. et al. (12 more authors) (2021) Laboratory safety of dupilumab in patients aged 6–11 years with severe atopic dermatitis : results from a phase III clinical trial. Pediatric Drugs, 23 (5). pp. 515-527. ISSN 1174-5878

Cork, M.J. orcid.org/0000-0003-4428-2428, Thaçi, D., Eichenfield, L.F. et al. (12 more authors) (2021) Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled, severe atopic dermatitis: results from an open‐label phase IIa study and subsequent phase III open‐label extension study. British Journal of Dermatology, 184 (5). pp. 857-870. ISSN 0007-0963

Paller, A.S., Siegfried, E.C., Thaçi, D. et al. (22 more authors) (2020) Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. Journal of the American Academy of Dermatology, 83 (5). pp. 1282-1293. ISSN 0190-9622